Print

Cancer Research Consortium of West Michigan

Rare Protocols

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.

Provided drugs are underlined

For more information, call the CRCWM Main office at 616.391.1230 or 800.336.5079

Rare

Cancer Type: Merkel Cell Carcinoma
Research Base: Alliance
Protocol: Alliance A091605
 

Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone vs anti-PD1 antibody plus SBRT  in advanced Merkel Cell Carcinoma

Cancer Type: Merkel Cell Carcinoma
Research Base: ECOG-ACRIN
Protocol: EA6174
 

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Cancer Type: Previously Treated AL Amyloidosis
Research Base: SWOG
Protocol: SWOG S1702
 

 A Phase II Study of Isatuximab  for Previously Treated AL Amyloidosis

Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma
Research Base: ACCRU
Protocol: EA3163
 

 Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Cancer Type: advanced neuroendocrine tumors
Research Base: Alliance
Protocol: Alliance A021602
 
Randomized, double-blinded phase III study of cabozantinib versus placebo in patients with advanced neuroendocrine tumors after progression on everolimus
(CABINET)
Cancer Type: Thymic Carcinoma
Research Base: SWOG
Protocol: SWOG S1701
 

A Randomized Phase II Trial of Carboplatin-Paclitaxel with or Without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Cancer Type: Inflammatory Breast Cancer
Research Base: SWOG
Protocol: SWOG S1706
 

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Cancer Type: Nasopharyngeal Carcinoma
Research Base: NRG
Protocol: NRG HN001
 

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Cancer Type: rare genitourinary tumors
Research Base: Alliance
Protocol: Alliance A031702
 

Phase II study of cabozantinib in combination with nivolumab and ipilimumab in rare genitourinary tumors

Cancer Type: ALK Positive Non Squamous NSCLC
Research Base: NRG
Protocol: NRG LU003
 

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol

Cancer Type: Locoregionally Advanced Head and Neck Cancer
Research Base: NRG
Protocol: NRG HN004
 

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin